Sai Parenterals Reports Q2 Net Profit Of ₹10.5 Crore Versus ₹6.35 Crore YoY

Market snapshot: Sai Parenterals Limited has reported its consolidated financial results for the second quarter, delivering top-line expansion and net profit growth driven by international contract development and manufacturing operations.

Data Snapshot

• Consolidated Q2 revenue reached ₹195 crore, up from ₹53.5 crore in the year-ago period.
• Consolidated net profit for the quarter rose to ₹10.5 crore compared to ₹6.35 crore in Q2 of the previous fiscal year.
• EBITDA surged to ₹40.3 crore from ₹11.4 crore YoY, while EBITDA margin stood at 20.67% compared to 21.41% in the prior year.

What's Changed

• Revenue increased to ₹195 crore from ₹53.5 crore YoY.
• EBITDA expanded to ₹40.3 crore from ₹11.4 crore YoY.
• Consolidated PAT increased to ₹10.5 crore from ₹6.35 crore YoY.
• EBITDA margin contracted by 74 basis points YoY to 20.67%.

Key Takeaways

• Top-line revenue grew strongly on account of expanded regulated market supply agreements and overseas commercial consolidation.
• EBITDA performance scaled to ₹40.3 crore while maintaining a double-digit margin profile.
• Net profit increased to ₹10.5 crore, demonstrating execution across formulation and CDMO business segments.

SAHI Perspective

The strong top-line performance highlights financial contribution from integrated international supply contracts. While EBITDA margin experienced a minor 74 bps contraction YoY to 20.67%, absolute operating profits expanded substantially.

Market Implications

The operating scale improves medium-term earnings visibility for the company across regulated export markets.

Trading Signals

Market Bias: Bullish

Revenue growth to ₹195 crore and net profit growth to ₹10.5 crore reflect strong underlying commercial trajectory.

Overweight: Pharmaceuticals, Healthcare / CDMO

Trigger Factors:

• Sustained execution of long-term OTC supply contracts
• Integration of R&D assets for complex injectables
• Maintenance of quarterly EBITDA margins above 20%

Time Horizon: Medium-term (3-12 months)

Industry Context

Indian CDMO and formulation exporters continue to scale operations by building multi-year regulatory partnerships across Australia and international markets.

Key Risks to Watch

• Raw material input cost volatility
• Regulatory oversight in international markets
• Foreign exchange rate fluctuations

Recent Developments

In August 2026, Australian subsidiary Noumed Pharmaceuticals renewed a 3-year OTC supply agreement worth AUD 30 million (~₹204 crore). In September 2026, research subsidiary SP Analytics agreed to acquire a 60% stake in Prathyak Laboratories for ₹18.02 crore.

Closing Insight

Sai Parenterals' Q2 operational update demonstrates strong momentum as regulated market contracts deliver scale.

High Performance Trading with SAHI.